Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Narrower Indication, New Studies Are Likely Riffs For Jazz Fibromyalgia Drug

Executive Summary

Jazz Pharmaceuticals will likely have to narrow the proposed indication for its fibromyalgia drug JZP-6 (sodium oxybate) following a "complete response" letter from FDA, but that appears to be only the first step for the product.

You may also be interested in...



REMS Lawsuit Possible After US FDA Approves Generic Xyrem

FDA waives requirement that Roxane's generic use same REMS as the brand; Jazz ‘intends to evaluate all potential challenges.’ Launch of generic still depends on patent litigation.

REMS Lawsuit Possible After US FDA Approves Generic Xyrem

FDA waives requirement that Roxane's generic use same REMS as the brand; Jazz ‘intends to evaluate all potential challenges.’ Launch of generic still depends on patent litigation.

Xyrem REMS Grudgingly Approved; FDA Worries About Blocked Generics

FDA approves a Risk Evaluation & Mitigation Strategy for Jazz Pharmaceutical’s Xyrem under protest; the agency says the single-pharmacy distribution plan for the narcolepsy treatment has the potential to block generic competitors from the market. FDA and Jazz had been working for seven years to agree to a REMS that confirms to the requirements under the FDA Amendments Act of 2007.

Related Content

Topics

UsernamePublicRestriction

Register

PS052726

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel